An Old AML Drug Revisited

Acute myeloid leukemia (AML) is a heterogeneous hematologic cancer whose wide range of outcomes probably reflects the accumulation of various acquired mutations that block the differentiation of blood-cell progenitors or confer a proliferative advantage to the malignant clone. Current therapies can cure approximately 40% of young patients, but outcomes are much worse in patients over the age of 60 years, who constitute the majority of cases of AML.An older age, a poor performance status, a high white-cell count, previous exposure to genotoxic agents, or the diagnosis of a myelodysplastic syndrome preceding the diagnosis of AML all negatively influence the . . .